En español
NIDA

MDMA (Ecstasy) Abuse

References

  1. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1993;8(2):171-176. doi:10.1038/npp.1993.19.
  2. Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3(4):265-279.
  3. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics. 1997;100(4):705-708.
  4. SAMHSA. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville (MD): SAMHSA; 2017. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf.
  5. Passie T, Benzenhöfer U. The History of MDMA as an Underground Drug in the United States, 1960–1979. J Psychoactive Drugs. 2016;48(2):67-75. doi:10.1080/02791072.2015.1128580.
  6. Kiyatkin EA, Kim AH, Wakabayashi KT, Baumann MH, Shaham Y. Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. J Neurosci Off J Soc Neurosci. 2014;34(23):7754-7762. doi:10.1523/JNEUROSCI.0506-14.2014.
  7. Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 2011;90(2):246-255. doi:10.1038/clpt.2011.78.
  8. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002;162(4):396-405. doi:10.1007/s00213-002-1131-1.
  9. Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol CJASN. 2008;3(6):1852-1860. doi:10.2215/CJN.02080508.
  10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987;241(1):338-345.
  11. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci Off J Soc Neurosci. 1999;19(12):5096-5107.
  12. O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci Off J Soc Neurosci. 1988;8(8):2788-2803.
  13. Biezonski DK, Meyer JS. The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis. Curr Neuropharmacol. 2011;9(1):84-90. doi:10.2174/157015911795017146.
  14. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 2000;68(6):719-725.
  15. Gold LH, Koob GF, Geyer MA. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther. 1988;247(2):547-555.
  16. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1988;1(4):273-277.
  17. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of “Ecstacy” users and their experiences with the drug. Br J Addict. 1992;87(8):1161-1172.
  18. EMCDDA. MDMA (“Ecstasy”) drug profile. January 2015. http://www.emcdda.europa.eu/publications/drug-profiles/mdma.
  19. DEA. Drugs of Abuse. 2015 Edition: A DEA Resource Guide. 2015. http://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf#page=62.
  20. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med. 1999;16(3):194-197.
  21. Baggott M, Heifets B, Jones R, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. J Am Med Assoc. 2000;284(17):2190.
  22. Tanner-Smith EE. Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. Drug Alcohol Depend. 2006;83(3):247-254. doi:10.1016/j.drugalcdep.2005.11.016.
  23. DEA. Microgram Bulletin. December 2008. https://www.dea.gov/pr/micrograms/2008/mg1208.pdf. Accessed September 19, 2016.
  24. Community Epidemiology Work Group. Proceedings of the Community Epidemiology Work Group. NIDA; 2014. http://www.drugabuse.gov/sites/default/files/cewgjune2014.pdf.
  25. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470. doi:10.1111/j.1476-5381.2012.02145.x.
  26. NDEWS. NDEWS News.; 2015. http://ndews.umd.edu/sites/ndews.umd.edu/files/NDEWS%20News%20Issue%201%20August%202015%20Final.pdf.
  27. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2000;22(5):513-521. doi:10.1016/S0893-133X(99)00148-7.
  28. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1998;19(4):241-251. doi:10.1016/S0893-133X(98)00013-X.
  29. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav. 2004;29(4):743-752. doi:10.1016/j.addbeh.2004.02.022.
  30. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999;55(1-2):105-115.
  31. DEA. Drug Fact Sheet: Ecstasy or MDMA. http://www.dea.gov/druginfo/drug_data_sheets/Ecstacy.pdf. Accessed February 25, 2016.
  32. Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol Oxf Engl. 2005;19(1):71-83. doi:10.1177/0269881105048900.
  33. Bernschneider-Reif S, Oxler F, Freudenmann RW. The origin of MDMA (“ecstasy”)--separating the facts from the myth. Pharm. 2006;61(11):966-972.
  34. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addict Abingdon Engl. 2006;101(9):1241-1245. doi:10.1111/j.1360-0443.2006.01511.x.
  35. Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? Am J Psychother. 1986;40(3):393-404.
  36. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol. 2001;16(8):557-577. doi:10.1002/hup.351.
  37. DEA. Schedules of Controlled Substances; Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act; Remand. 1988;53(34):5156.
  38. DEA. Orangebook. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. November 2015. http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf.
  39. White CM. 3,4-Methylenedioxymethamphetamine’s (MDMA’s) Impact on Posttraumatic Stress Disorder. Ann Pharmacother. 2014;48(7):908-915. doi:10.1177/1060028014532236.
  40. Parrott AC. The potential dangers of using MDMA for psychotherapy. J Psychoactive Drugs. 2014;46(1):37-43. doi:10.1080/02791072.2014.873690.
  41. Grob C. MDMA research: preliminary investigations with human subjects. Int J Drug Policy. 1998;9(2):119-124.
  42. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res. 1996;73(1-2):103-107.
  43. SAMHSA. National Survey on Drug Use and Health, 2002-2014. Rockville, MD: SAMHSA; 2015. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf.
  44. SAMHSA. Results from the 2004 National Survey on Drug Use and Health: National Findings. Rockville, MD: SAMHSA; 2005. http://archive.samhsa.gov/data/NSDUH/2k4nsduh/2k4results/2k4results.pdf.
  45. Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, The University of Michigan; 2017.
  46. Palamar JJ, Kamboukos D. An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States. Subst Use Misuse. 2014;49(13):1774-1783. doi:10.3109/10826084.2014.926933.
  47. SAMHSA. Drug Abuse Warning Network, 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: SAMHSA; 2013. http://www.samhsa.gov/data/sites/default/files/Nation_2011_Illicit.xls.
  48. SAMHSA. Treatment Episode Data Set (TEDS): 2004-2014. National Admissions to Substance Abuse Treatment Services. Rockville, MD; 2016. https://wwwdasis.samhsa.gov/dasis2/teds_pubs/2014_teds_rpt_natl.pdf.
  49. Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, Volume 1: Highlights and Executive Summary. NIDA; 1999. http://archives.drugabuse.gov/pdf/cewg/CEWG1299.pdf.
  50. SAMHSA. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. SAMHSA; 2015. http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm#idtextanchor030.
  51. SAMHSA. Risk and Protective Factors and Initiation of Substance Use: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: SAMHSA; 2015. https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FRR4-2014rev/NSDUH-DR-FRR4-2014.pdf.
  52. Chow C, Vallance K, Stockwell T, et al. Sexual identity and drug use harm among high-risk, active substance users. Cult Health Sex. 2013;15(3):311-326. doi:10.1080/13691058.2012.754054.
  53. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX, Hell D. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2000;23(4):388-395. doi:10.1016/S0893-133X(00)00130-5.
  54. Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9(11):1645-1652. doi:10.1093/scan/nst161.
  55. Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway GP, Mendelson JE. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol Oxf Engl. February 2016. doi:10.1177/0269881115626348.
  56. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154(2):161-168.
  57. Davison D, Parrott AC. Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects. Hum Psychopharmacol Clin Exp. 1997;12:221-226.
  58. Le Roux G, Bruneau C, Lelièvre B, et al. Recreational phenethylamine poisonings reported to a French poison control center. Drug Alcohol Depend. 2015;154:46-53. doi:10.1016/j.drugalcdep.2015.05.048.
  59. Armenian P, Mamantov TM, Tsutaoka BT, et al. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series. J Intensive Care Med. 2013;28(4):252-258. doi:10.1177/0885066612445982.
  60. Dafters RI, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine. Psychopharmacology (Berl). 1998;138(2):207-212.
  61. Ridpath A, Driver CR, Nolan ML, et al. Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(50):1195-1198.
  62. Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(9):2206-2209. doi:10.1093/ndt/gft192.
  63. Baggott MJ, Garrison KJ, Coyle JR, et al. MDMA Impairs Response to Water Intake in Healthy Volunteers. Adv Pharmacol Sci. 2016;2016:2175896. doi:10.1155/2016/2175896.
  64. van Dijken GD, Blom RE, Hené RJ, Boer WH, NIGRAM Consortium  null. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(9):2277-2283. doi:10.1093/ndt/gft023.
  65. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000;133(12):969-973.
  66. Cohen RS. Subjective reports on the effects of the MDMA (’ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(7):1137-1145.
  67. Lamers CTJ, Ramaekers JG, Muntjewerff ND, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol Oxf Engl. 2003;17(4):379-387.
  68. Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos Biol Fate Chem. 2014;42(1):119-125. doi:10.1124/dmd.113.053678.
  69. da Silva DD, Silva E, Carvalho F, Carmo H. Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations. J Appl Toxicol JAT. 2014;34(6):618-627. doi:10.1002/jat.2885.
  70. Camarasa J, Pubill D, Escubedo E. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res. 2006;1111(1):72-82. doi:10.1016/j.brainres.2006.06.087.
  71. Dias da Silva D, Carmo H, Silva E. The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines? Arch Toxicol. 2013;87(1):111-122. doi:10.1007/s00204-012-0929-9.
  72. Angoa-Pérez M, Kane M, Briggs D, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem. 2013;125(1):102-110.
  73. Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther. 2009;86(2):160-166. doi:10.1038/clpt.2009.62.
  74. Navarro-Zaragoza J, Ros-Simó C, Milanés M-V, Valverde O, Laorden M-L. Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress. PloS One. 2015;10(10):e0141502. doi:10.1371/journal.pone.0141502.
  75. Ros-Simó C, Ruiz-Medina J, Valverde O. Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice. Psychopharmacology (Berl). 2012;221(3):511-525. doi:10.1007/s00213-011-2598-4.
  76. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther. 2002;302(3):898-907.
  77. Curran HV, Travill RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): week-end “high” followed by mid-week low. Addict Abingdon Engl. 1997;92(7):821-831.
  78. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl). 1998;139(3):261-268.
  79. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of “ecstasy” (MDMA) consumption in 430 regular users. Hum Psychopharmacol. 2003;18(7):507-517. doi:10.1002/hup.529.
  80. Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology (Berl). 2002;161(1):23-31. doi:10.1007/s00213-001-0995-9.
  81. Droogmans S, Cosyns B, D’haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol. 2007;100(9):1442-1445. doi:10.1016/j.amjcard.2007.06.045.
  82. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63(6):1223-1229. doi:10.1124/mol.63.6.1223.
  83. Morgan MJ. Memory deficits associated with recreational use of “ecstasy” (MDMA). Psychopharmacology (Berl). 1999;141(1):30-36.
  84. Wagner D, Tkotz S, Koester P, Becker B, Gouzoulis-Mayfrank E, Daumann J. Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study. Front Neurosci. 2015;9:445. doi:10.3389/fnins.2015.00445.
  85. May AL, Parrott AC. Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study. Hum Psychopharmacol. 2015;30(4):272-275. doi:10.1002/hup.2432.
  86. Novoa RA, Ompad DC, Wu Y, Vlahov D, Galea S. Ecstasy use and its association with sexual behaviors among drug users in New York City. J Community Health. 2005;30(5):331-343.
  87. Theall KP, Elifson KW, Sterk CE. Sex, touch, and HIV risk among ecstasy users. AIDS Behav. 2006;10(2):169-178. doi:10.1007/s10461-005-9059-1.
  88. Degenhardt L. Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference? Cult Health Sex. 2005;7(6):599-614. doi:10.1080/13691050500349875.
  89. Gough B, Ali SF, Slikker W, Holson RR. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav. 1991;39(3):619-623.
  90. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol. 1987;36(5):747-755.
  91. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synap N Y N. 2001;39(1):32-41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
  92. Sabol KE, Seiden LS. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res. 1998;806(1):69-78.
  93. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol. 1992;215(2-3):153-160.
  94. Verrico CD, Lynch L, Fahey MA, Fryer A-K, Miller GM, Madras BK. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol Oxf Engl. 2008;22(2):187-202. doi:10.1177/0269881107083639.
  95. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA (“Ecstasy”) users. Neurology. 1998;51(6):1532-1537.
  96. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology. 2000;55(2):294-296.
  97. Cuyas E, Robledo P, Pizarro N, et al. 3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. Neurotox Res. 2014;25(2):161-169. doi:10.1007/s12640-013-9416-1.
  98. Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016;8(1). doi:10.3390/nu8010056.
  99. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (’ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend. 1998;52(1):85-90.
  100. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug Alcohol Depend. 2000;60(1):105-110.
  101. Verkes RJ, Gijsman HJ, Pieters MS, et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl). 2001;153(2):196-202.
  102. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA (’ecstasy’). Br J Psychol Lond Engl 1953. 2000;91 ( Pt 2):181-188.
  103. Bosch OG, Wagner M, Jessen F, et al. Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PloS One. 2013;8(4):e61234. doi:10.1371/journal.pone.0061234.
  104. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasylong-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry J Ment Sci. 1999;175:186-188.
  105. Mueller F, Lenz C, Steiner M, et al. Neuroimaging in moderate MDMA use: A systematic review. Neurosci Biobehav Rev. 2015;62:21-34. doi:10.1016/j.neubiorev.2015.12.010.
  106. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav. 2002;71(4):845-855.
  107. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend. 2002;68(2):195-207.
  108. Singer LT, Moore DG, Min MO, et al. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. Hum Psychopharmacol. 2015;30(4):290-294. doi:10.1002/hup.2459.
  109. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci Off J Soc Neurosci. 2001;21(9):3228-3235.
  110. Williams MT, Skelton MR, Longacre ID, et al. Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine. Toxicol Rep. 2014;1:699-706. doi:10.1016/j.toxrep.2014.08.018.
  111. Colado MI, O’Shea E, Granados R, Misra A, Murray TK, Green AR. A study of the neurotoxic effect of MDMA (’ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol. 1997;121(4):827-833. doi:10.1038/sj.bjp.0701201.
  112. Koprich JB, Chen E-Y, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol. 2003;25(5):509-517.
  113. Canales JJ, Ferrer-Donato A. Prenatal exposure to alcohol and 3,4-methylenedioxymethamphetamine (ecstasy) alters adult hippocampal neurogenesis and causes enduring memory deficits. Dev Neurosci. 2014;36(1):10-17. doi:10.1159/000356820.
  114. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1-10. doi:10.1016/j.drugalcdep.2009.09.009.
  115. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC. MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci. 2007;26(11):3229-3236. doi:10.1111/j.1460-9568.2007.05932.x.
  116. Schenk S, Aronsen D. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (’Ecstasy’) Substance Use Disorder. Curr Top Behav Neurosci. December 2015. doi:10.1007/7854_2015_421.
  117. Cottler LB, Leung KS, Abdallah AB. Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. Addict Abingdon Engl. 2009;104(10):1679-1690. doi:10.1111/j.1360-0443.2009.02649.x.
  118. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16(8):599-606. doi:10.1002/hup.343.
  119. Davis AK, Rosenberg H. The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. J Psychoactive Drugs. 2014;46(2):154-161. doi:10.1080/02791072.2014.901586.
  120. Falck RS, Carlson RG, Wang J, Siegal HA. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol Depend. 2004;74(1):45-54. doi:10.1016/j.drugalcdep.2003.11.009.
  121. Champion KE, Newton NC, Stapinski LA, Teesson M. Effectiveness of a universal Internet-based prevention program for ecstasy and new psychoactive substances: a cluster randomised controlled trial. Addict Abingdon Engl. February 2016. doi:10.1111/add.13345.
  122. Ciudad-Roberts A, Camarasa J, Pubill D, Escubedo E. Heteromeric nicotinic receptors are involved in the sensitization and addictive properties of MDMA in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:201-209. doi:10.1016/j.pnpbp.2013.02.013.
  123. Rodríguez-Arias M, Valverde O, Daza-Losada M, Blanco-Gandía MC, Aguilar MA, Miñarro J. Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:77-84. doi:10.1016/j.pnpbp.2013.07.013.
  124. Roger-Sánchez C, Rodríguez-Arias M, Miñarro J, Aguilar MA. Involvement of 5-hydroxytryptamine 5-HT₃ serotonergic receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA. Eur J Pharmacol. 2013;714(1-3):132-141. doi:10.1016/j.ejphar.2013.06.005.
  125. Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PloS One. 2012;7(5):e36476. doi:10.1371/journal.pone.0036476.
  126. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013;33(5):658-666. doi:10.1097/JCP.0b013e3182979d32.

This page was last updated September 2017

Get this Publication

Cite this article

NIDA. (2017, September 26). MDMA (Ecstasy) Abuse. Retrieved from https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse

press ctrl+c to copy
NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.

Lesson Plan and Activity Finder